SCHEMBL10174703

SCHEMBL10174703

CCc1cnccc1C(=O)SC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 8/20 0.41
KDM6B O15054 4/20 0.41
KMT2A Q03164 3/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
MEN1 O00255 2/20 0.38
KDM4A O75164 1/20 0.38
MAPT P10636 1/20 0.38
THRB P10828 1/20 0.38
KDM4D Q6B0I6 1/20 0.38
GLA P06280 1/20 0.38
GAA P10253 1/20 0.38
SIRT3 Q9NTG7 1/20 0.37
RAB9A P51151 4/20 0.37
POLB P06746 1/20 0.35
CYP2E1 P05181 1/20 0.35
CYP2C8 P10632 1/20 0.35
CYP2D6 P10635 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30100781 0.79 KDM4C (0.56) KDM4CKDM6BKMT2AKDM4EALDH1A1
SCHEMBL115648 0.79 KDM4C (0.56) KDM4CKDM6BKMT2AKDM4EALDH1A1
SCHEMBL11236770 0.79 KDM4C (0.44) KDM4CKDM6BKMT2AKDM4EALDH1A1
SCHEMBL1026384 0.78 KDM4C (0.42) KDM4CKDM6BKMT2AKDM4EALDH1A1
SCHEMBL8594489 0.78 TDP1 (0.56) KDM4CKDM6BKMT2AKDM4EALDH1A1
Hydrochloric Acid SCHEMBL1026385 0.78 KDM4C (0.54) KDM4CKDM6BKMT2AKDM4EALDH1A1
SCHEMBL16684319 0.75 KDM4C (0.41) KDM4CKDM6BKMT2AKDM4EALDH1A1
SCHEMBL845125 0.75 ALDH1A1 (0.62) KDM4CKDM6BKMT2AKDM4EALDH1A1
SCHEMBL14618137 0.75 KDM4C (0.44) KDM4CKDM6BKMT2AKDM4EALDH1A1
SCHEMBL19840668 0.75 KDM4C (0.44) KDM4CKDM6BKMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178743-A1 NOVEL ADENINE COMPOUND AND USE THEREOF DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-07-12 US disclosed
US-8148371-B2 Adenine compound and use thereof DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-04-03 US disclosed
US-20100256118-A1 NOVEL ADENINE COMPOUND AND USE THEREOF DAINIPPON SUMITOMO PHARMA CO.,LTD. (JP) 2010-10-07 US disclosed
US-7754728-B2 Adenine compound and use thereof DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2010-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256118-A1 NOVEL ADENINE COMPOUND AND USE THEREOF ADORA1, P2RY10, HRH4 KDM4C 2562/4885KDM6B 2462/4885KMT2A 2009/4885
US-20120178743-A1 NOVEL ADENINE COMPOUND AND USE THEREOF ADORA1, HRH4, P2RY10 KDM4C 2451/4885KDM6B 2293/4885KMT2A 1817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.